Remedy Plan Therapeutics

Funding and NIH signals

• NIH award NIH awarded $1.18M (SBIR Phase II 1R44CA314487-01, new, notice Sep 17, 2026). NIH RePORTER 1R44CA314487-01 (Sep 17, 2026)
  Evidence (1 event)

  • Sep 17, 2026 · NIH RePORTER 1R44CA314487-01
    Organization: REMEDY PLAN; City/State: GAITHERSBURG, MD; Project number: 1R44CA314487-01; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-17; FY total cost (award amount): 1181436; Administering IC: National Cancer Institute; Project title: Preclinical validation of NAMPT and PARP inhibitor combinations for breast cancer to support clinical studies; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

• Raise Undisclosed round · more than $18M · announced May 13, 2025 Company release ↗
  Source quote

  • May 13, 2025 · Company release ↗
    “-- Remedy Plan Therapeutics (Remedy Plan), a privately-held, clinical-stage pharmaceutical company developing novel, hyperbolic NAMPT inhibitors, today announced the company has raised over $18 million in an oversubscribed insider financing round”

Raises announced in these releases: $18M disclosed.

From the company’s own releases; this list is partial. All raises and deals